ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.686,60
1,07%
S&P 500
5.212,89
0,49%
Dow Jones
39.371,93
0,81%
Euro vs US Dollar
1,07787
0,30%
Bitcoin
62.203,13
1,66%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Photocure Asa (0IMT)

  7. Photocure Asa (0IMT) News

0IMT

Photocure Asa (0IMT)

Photocure Asa
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:0IMT
DatumZeitQuelleÜberschriftSymbolFirma
09/08/202308h30PR Newswire (US)Photocure ASA: Results for the second quarter and first half of 2023LSE:0IMTPhotocure Asa
09/08/202308h26PR Newswire (US)Photocure ASA: Results for the second quarter and first half of 2023LSE:0IMTPhotocure Asa
06/07/202310h57PR Newswire (US)Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in ChinaLSE:0IMTPhotocure Asa
06/07/202310h54PR Newswire (US)Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in ChinaLSE:0IMTPhotocure Asa
10/05/202308h18PR Newswire (US)Photocure ASA: Results for the first quarter of 2023LSE:0IMTPhotocure Asa
10/05/202308h15PR Newswire (US)Photocure ASA: Results for the first quarter of 2023LSE:0IMTPhotocure Asa
04/05/202313h48PR Newswire (US)Photocure ASA - Correction: Annual general meeting heldLSE:0IMTPhotocure Asa
04/05/202313h44PR Newswire (US)Photocure ASA - Correction: Annual general meeting heldLSE:0IMTPhotocure Asa
03/05/202318h58PR Newswire (US)Photocure ASA - Annual general meeting heldLSE:0IMTPhotocure Asa
03/05/202318h53PR Newswire (US)Photocure ASA - Annual general meeting heldLSE:0IMTPhotocure Asa
03/05/202311h53PR Newswire (US)Photocure ASA: Invitation to presentation of first quarter 2023 financial resultsLSE:0IMTPhotocure Asa
03/05/202311h52PR Newswire (US)Photocure ASA: Invitation to presentation of first quarter 2023 financial resultsLSE:0IMTPhotocure Asa
02/05/202317h35PR Newswire (US)Photocure: Nordic registry clinical data and multiple scientific programs at AUA 2023 Congress reinforce the benefits of Blue Light CystoscopyLSE:0IMTPhotocure Asa
02/05/202317h30PR Newswire (US)Photocure: Nordic registry clinical data and multiple scientific programs at AUA 2023 Congress reinforce the benefits of Blue Light CystoscopyLSE:0IMTPhotocure Asa
12/04/202316h14PR Newswire (US)Photocure ASA: Annual Report 2022LSE:0IMTPhotocure Asa
12/04/202316h14PR Newswire (US)Photocure ASA - Notice of the Annual General Meeting 3 May 2023LSE:0IMTPhotocure Asa
12/04/202316h12PR Newswire (US)Photocure ASA - Notice of the Annual General Meeting 3 May 2023LSE:0IMTPhotocure Asa
12/04/202316h11PR Newswire (US)Photocure ASA: Annual Report 2022LSE:0IMTPhotocure Asa
14/03/202308h53PR Newswire (US)Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancerLSE:0IMTPhotocure Asa
14/03/202308h40PR Newswire (US)Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancerLSE:0IMTPhotocure Asa
23/02/202308h29PR Newswire (US)Photocure ASA: Results for the fourth quarter of 2022LSE:0IMTPhotocure Asa
23/02/202308h27PR Newswire (US)Photocure ASA: Results for the fourth quarter of 2022LSE:0IMTPhotocure Asa
20/02/202307h43PR Newswire (US)Clinical data presented at ASCO GU demonstrates reduced risk of recurrence in non-muscle invasive bladder cancer with the use of BLCLSE:0IMTPhotocure Asa
03/01/202307h47PR Newswire (US)New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursementLSE:0IMTPhotocure Asa
03/01/202307h45PR Newswire (US)New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursementLSE:0IMTPhotocure Asa
05/12/202208h08PR Newswire (US)New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO MeetingLSE:0IMTPhotocure Asa
05/12/202208h03PR Newswire (US)New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO MeetingLSE:0IMTPhotocure Asa
07/11/202208h11PR Newswire (US)Photocure: CMS improves Medicare reimbursement for Blue Light Cystoscopy with Cysview and expands access in the surveillance settingLSE:0IMTPhotocure Asa
02/11/202208h38PR Newswire (US)Photocure ASA: Results for the third quarter of 2022LSE:0IMTPhotocure Asa
02/11/202208h37PR Newswire (US)Photocure ASA: Results for the third quarter of 2022LSE:0IMTPhotocure Asa
 Showing the most relevant articles for your search:LSE:0IMT

Kürzlich von Ihnen besucht

TG
MBG
MercedesBenz
TG
LHA
Deutsche Lufthansa
AMEX
XLE
Energy Select Sector SPDR
NYSE
MRK
Merck
TG
TUI1
Tui
FX
EURJPY
Euro vs Yen
NASDAQ
AMZN
Amazon.com
NASDAQ
QQQ
Invesco QQQ Trust Series 1
TG
NOV
Novo Nordisk
CCOM
SILVER
SILVER
TG
DBK
Deutsche Bank
PM
XAUUSD
Gold vs US Dollar
DBI
SDXP
SDAX
AMEX
SPY
SPDR S&P 500
TG
RHM
Rheinmetall
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten